Last reviewed · How we verify
Calcium Channel Blocker & Adenosine
At a glance
| Generic name | Calcium Channel Blocker & Adenosine |
|---|---|
| Sponsor | Singapore General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- Sex Difference of Coronary Microvascular Dysfunction in Patients With Non-obstructive Coronary Artery Disease
- Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients (PHASE3)
- Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions (NA)
- The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease
- The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) (PHASE4)
- Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium Channel Blocker & Adenosine CI brief — competitive landscape report
- Calcium Channel Blocker & Adenosine updates RSS · CI watch RSS
- Singapore General Hospital portfolio CI